Sirna Therapeutics Appoints Gregory Weaver as Chief Financial Officer

07 Feb, 2006, 00:00 ET from Sirna Therapeutics, Inc.

    SAN FRANCISCO, Feb. 7 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc.
 (Nasdaq:   RNAI), a leading RNAi therapeutics company, announced today the
 appointment of Gregory Weaver, CPA, MBA as the Company's Senior Vice President
 and Chief Financial Officer.  Mr. Weaver will direct and oversee Sirna's
 financial management, accounting activities and investor relations.  He will
 report to Howard W. Robin, President and Chief Executive Officer of Sirna.
 Mr. Weaver's appointment will be effective as of February 13, 2006.
     "We are pleased to have Greg join the team at Sirna," stated Howard Robin.
 "He is a seasoned professional who has proven his ability to engage and work
 with the investment community.  Greg brings an outstanding set of financial,
 transaction and strategic leadership skills to our team which we feel will be
 instrumental in building value for the organization both near and long term."
     Mr. Weaver has extensive experience with both publicly traded and private
 companies, most recently serving as the Chief Financial Officer of Nastech
 Pharmaceutical Company and prior to that, the Chief Financial Officer at ILEX
 Oncology.  Throughout his career, Mr. Weaver has managed revenue and profit
 growth, manufacturing and R&D investments and has raised over $400 million in
 capital market transactions.  In addition, Mr. Weaver has either led or
 participated in mergers, acquisitions, in and out-licensing transactions
 valued at over $200 million.
     "I am excited to join Sirna Therapeutics at a time when the company is
 looking to bring a second compound into the clinic," commented Mr. Weaver.
 "The work being pioneered by Sirna presents an exciting opportunity for the
 biotech and investment communities.  I look forward to working closely with
 the team at Sirna in continuing to build awareness of both their scientific
 breakthroughs and their industry leading efforts in developing RNAi-based
 therapeutics."
     Mr. Weaver sits on the Board of Director's Executive Committee for the
 Washington Biotech and Biomedical Association and is currently a member of the
 Licensing Executive Society and the American Institute of CPA's.  Mr. Weaver
 received his BS degree from Trinity University in San Antonio, Texas and his
 MBA from the Boston College Graduate School of Management.
 
     About Sirna Therapeutics
     Sirna Therapeutics is a clinical-stage biotechnology company developing
 RNAi-based therapies for serious diseases and conditions, including
 age-related macular degeneration (AMD), hepatitis B and C, dermatology,
 asthma, Huntington's disease, diabetes and oncology.  Sirna Therapeutics has
 presented interim Phase 1 clinical trial data for its most advanced compound,
 Sirna-027, a chemically optimized siRNA targeting the clinically validated
 vascular endothelial growth factor pathway to treat AMD.  Sirna-027, which has
 been partnered with Allergan, Inc., continues to demonstrate that it is safe
 and well tolerated with 100% of patients showing visual acuity stabilization
 after eight weeks from a single injection.  In addition, Sirna recently
 announced that it has selected Sirna-AV34, a systemically delivered, optimized
 siRNA compound, as its candidate for advancement to human clinical testing
 against Hepatitis C virus.  Sirna has a leading intellectual property
 portfolio in RNAi with 49 issued patents and over 240 pending applications
 worldwide.  More information on Sirna Therapeutics is available on the
 Company's web site at http://www.sirna.com.
 
     Safe Harbor Statement
     Statements in this press release which are not strictly historical are
 "forward-looking" statements which should be considered as subject to many
 risks and uncertainties.  For example, most drug candidates do not become
 approved drugs.  Moreover, Sirna's ability to develop products and operate as
 a going concern requires significant cash to fund its operating programs.
 Additional risks and uncertainties include Sirna's early stage of development
 and short operating history, Sirna's history and expectation of losses and
 need to raise capital, Sirna's need to obtain clinical validation and
 regulatory approval for products, Sirna's need to obtain and protect
 intellectual property, risk of third-party patent infringement claims, Sirna's
 need to attract and retain qualified personnel, Sirna's need to engage
 collaborators, availability of materials for product manufacturing, the highly
 competitive nature of the pharmaceutical market, the limited trading volume
 and history of volatility of Sirna's common stock, Sirna's concentration of
 stock ownership, and risks from relocating Sirna headquarters.  These and
 additional risk factors are identified in Sirna's Securities and Exchange
 Commission filings, including the Forms 10-K and 10-Q and in other SEC
 filings.  Sirna undertakes no obligation to revise or update any
 forward-looking statements in order to reflect events or circumstances that
 may arise after the date of this release.
 
     Contacts:
     J. Michael French
     Senior Vice President, Corporate Development
     Sirna Therapeutics, Inc.
     (303) 449-6500
 
     Investors
     Francesca DeGrego
     The Ruth Group
     (646) 536-7024
     fdeGrego@theruthgroup.com
 
     Media
     Jason Rando
     The Ruth Group
     (646) 536-7025
     jrando@theruthgroup.com
 
 

SOURCE Sirna Therapeutics, Inc.
    SAN FRANCISCO, Feb. 7 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc.
 (Nasdaq:   RNAI), a leading RNAi therapeutics company, announced today the
 appointment of Gregory Weaver, CPA, MBA as the Company's Senior Vice President
 and Chief Financial Officer.  Mr. Weaver will direct and oversee Sirna's
 financial management, accounting activities and investor relations.  He will
 report to Howard W. Robin, President and Chief Executive Officer of Sirna.
 Mr. Weaver's appointment will be effective as of February 13, 2006.
     "We are pleased to have Greg join the team at Sirna," stated Howard Robin.
 "He is a seasoned professional who has proven his ability to engage and work
 with the investment community.  Greg brings an outstanding set of financial,
 transaction and strategic leadership skills to our team which we feel will be
 instrumental in building value for the organization both near and long term."
     Mr. Weaver has extensive experience with both publicly traded and private
 companies, most recently serving as the Chief Financial Officer of Nastech
 Pharmaceutical Company and prior to that, the Chief Financial Officer at ILEX
 Oncology.  Throughout his career, Mr. Weaver has managed revenue and profit
 growth, manufacturing and R&D investments and has raised over $400 million in
 capital market transactions.  In addition, Mr. Weaver has either led or
 participated in mergers, acquisitions, in and out-licensing transactions
 valued at over $200 million.
     "I am excited to join Sirna Therapeutics at a time when the company is
 looking to bring a second compound into the clinic," commented Mr. Weaver.
 "The work being pioneered by Sirna presents an exciting opportunity for the
 biotech and investment communities.  I look forward to working closely with
 the team at Sirna in continuing to build awareness of both their scientific
 breakthroughs and their industry leading efforts in developing RNAi-based
 therapeutics."
     Mr. Weaver sits on the Board of Director's Executive Committee for the
 Washington Biotech and Biomedical Association and is currently a member of the
 Licensing Executive Society and the American Institute of CPA's.  Mr. Weaver
 received his BS degree from Trinity University in San Antonio, Texas and his
 MBA from the Boston College Graduate School of Management.
 
     About Sirna Therapeutics
     Sirna Therapeutics is a clinical-stage biotechnology company developing
 RNAi-based therapies for serious diseases and conditions, including
 age-related macular degeneration (AMD), hepatitis B and C, dermatology,
 asthma, Huntington's disease, diabetes and oncology.  Sirna Therapeutics has
 presented interim Phase 1 clinical trial data for its most advanced compound,
 Sirna-027, a chemically optimized siRNA targeting the clinically validated
 vascular endothelial growth factor pathway to treat AMD.  Sirna-027, which has
 been partnered with Allergan, Inc., continues to demonstrate that it is safe
 and well tolerated with 100% of patients showing visual acuity stabilization
 after eight weeks from a single injection.  In addition, Sirna recently
 announced that it has selected Sirna-AV34, a systemically delivered, optimized
 siRNA compound, as its candidate for advancement to human clinical testing
 against Hepatitis C virus.  Sirna has a leading intellectual property
 portfolio in RNAi with 49 issued patents and over 240 pending applications
 worldwide.  More information on Sirna Therapeutics is available on the
 Company's web site at http://www.sirna.com.
 
     Safe Harbor Statement
     Statements in this press release which are not strictly historical are
 "forward-looking" statements which should be considered as subject to many
 risks and uncertainties.  For example, most drug candidates do not become
 approved drugs.  Moreover, Sirna's ability to develop products and operate as
 a going concern requires significant cash to fund its operating programs.
 Additional risks and uncertainties include Sirna's early stage of development
 and short operating history, Sirna's history and expectation of losses and
 need to raise capital, Sirna's need to obtain clinical validation and
 regulatory approval for products, Sirna's need to obtain and protect
 intellectual property, risk of third-party patent infringement claims, Sirna's
 need to attract and retain qualified personnel, Sirna's need to engage
 collaborators, availability of materials for product manufacturing, the highly
 competitive nature of the pharmaceutical market, the limited trading volume
 and history of volatility of Sirna's common stock, Sirna's concentration of
 stock ownership, and risks from relocating Sirna headquarters.  These and
 additional risk factors are identified in Sirna's Securities and Exchange
 Commission filings, including the Forms 10-K and 10-Q and in other SEC
 filings.  Sirna undertakes no obligation to revise or update any
 forward-looking statements in order to reflect events or circumstances that
 may arise after the date of this release.
 
     Contacts:
     J. Michael French
     Senior Vice President, Corporate Development
     Sirna Therapeutics, Inc.
     (303) 449-6500
 
     Investors
     Francesca DeGrego
     The Ruth Group
     (646) 536-7024
     fdeGrego@theruthgroup.com
 
     Media
     Jason Rando
     The Ruth Group
     (646) 536-7025
     jrando@theruthgroup.com
 
 SOURCE  Sirna Therapeutics, Inc.